Cirrus Therapeutics, an United Kingdom-based ocular immunology-focused biotech, announced Wednesday the close of an $11 million seed financing to advance its pipeline of gene and cell therapies aimed at improving quality of life and extending the ocular healthspan of patients with chronic blinding diseases.